Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 5
2023 2
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Transforming growth factor-β1 in regulatory T cell biology.
Moreau JM, Velegraki M, Bolyard C, Rosenblum MD, Li Z. Moreau JM, et al. Sci Immunol. 2022 Mar 18;7(69):eabi4613. doi: 10.1126/sciimmunol.abi4613. Epub 2022 Mar 18. Sci Immunol. 2022. PMID: 35302863 Free PMC article. Review.
Sex-biased adaptive immune regulation in cancer development and therapy.
Schafer JM, Xiao T, Kwon H, Collier K, Chang Y, Abdel-Hafiz H, Bolyard C, Chung D, Yang Y, Sundi D, Ma Q, Theodorescu D, Li X, Li Z. Schafer JM, et al. iScience. 2022 Jul 4;25(8):104717. doi: 10.1016/j.isci.2022.104717. eCollection 2022 Aug 19. iScience. 2022. PMID: 35880048 Free PMC article. Review.
SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling.
Zhao B, Gong W, Ma A, Chen J, Velegraki M, Dong H, Liu Z, Wang L, Okimoto T, Jones DM, Lei YL, Long M, Oestreich KJ, Ma Q, Xin G, Carbone DP, He K, Li Z, Wen H. Zhao B, et al. Nat Immunol. 2022 Nov;23(11):1588-1599. doi: 10.1038/s41590-022-01326-8. Epub 2022 Oct 20. Nat Immunol. 2022. PMID: 36266363 Free PMC article.
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.
Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz RM, Miao J, Song C, Wu D, Chan WK, Bezerra E, Epperla N, Voorhees TJ, Brammer J, Kittai AS, Bond DA, Sawalha Y, Sigmund A, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks K, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski S, Li Z, Huang X, Yang Y. Denlinger N, et al. Blood Adv. 2024 Jun 25;8(12):3140-3153. doi: 10.1182/bloodadvances.2023012073. Blood Adv. 2024. PMID: 38607381 Free PMC article.
Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity.
Li A, Chang Y, Song NJ, Wu X, Chung D, Riesenberg BP, Velegraki M, Giuliani GD, Das K, Okimoto T, Kwon H, Chakravarthy KB, Bolyard C, Wang Y, He K, Gatti-Mays M, Das J, Yang Y, Gewirth DT, Ma Q, Carbone D, Li Z. Li A, et al. J Immunother Cancer. 2022 Sep;10(9):e005433. doi: 10.1136/jitc-2022-005433. J Immunother Cancer. 2022. PMID: 36096533 Free PMC article.
12 results